Evidence map›Paper›PMID 21247147›Full record

ArticleBiochemistry2011

Functional characterization of mutations in inherited human cPLA₂ deficiency.

Kathleen A Reed, Dawn E Tucker, Ahmed Aloulou, David Adler, Farideh Ghomashchi, Michael H Gelb, Christina C Leslie, John A Oates, Olivier Boutaud

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Phospholipases: Where Do We Stand?Methods in molecular biology (Clifton, N.J.) · 2027
    Review
  2. A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. A PLA1-2 punch regulates the Golgi complex.Trends in cell biology · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kathleen A ReedDepartment of Medicine, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232-6602, United States.
Dawn E Tucker
Ahmed Aloulou
David Adler
Farideh Ghomashchi
Michael H Gelb
Christina C Leslie
John A Oates
Olivier Boutaud
University of Washington · USUniversity of Colorado Denver · US

Funding

THE PHARMACOLOGY OF ASPIRINP50HL081009 · NHLBI · VANDERBILT UNIVERSITY · PI OATES, JOHN ALEXANDER · 2006 to 2010
$16.3M
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATIONP50GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI MARNETT, LAWRENCE J. · 1985 to 2010
$15.0M
Therapeutic Modulation of Endothelial Cell TetrahydrobiopterinP01GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI ROBERTS, II, L JACKSON · 2011 to 2015
$9.5M
REGULATION OF PHOSPHOLIPASE A2 NUCLEAR TARGETINGR01HL061378 · NHLBI · NATIONAL JEWISH HEALTH · PI LESLIE, CHRISTINA CARROLL · 1999 to 2011
$4.1M
Regulation and Function of Cytosolic Phospholipase A2R01HL050040 · NHLBI · UNIVERSITY OF WASHINGTON · PI GELB, MICHAEL H · 1993 to 2012
$2.4M
NHLBI NIH HHS HL50040NHLBI NIH HHS HL61378NHLBI NIH HHS HL81009NHLBI NIH HHS P50 HL081009NHLBI NIH HHS R01 HL050040NHLBI NIH HHS R01 HL061378NIGMS NIH HHS GM15431NIGMS NIH HHS P01 GM015431NIGMS NIH HHS P50 GM015431
6 · The paper itself

Abstract

Group IVA cytosolic phospholipase A(2) (cPLA(2)α) catalyzes the first step in the arachidonic acid cascade leading to the synthesis of important lipid mediators, the prostaglandins and leukotrienes. We previously described a patient deficient in cPLA(2)α activity, which was associated with mutations in both alleles encoding the enzyme. In this paper, we describe the biochemical characterization of each of these mutations. Using saturating concentrations of calcium, we showed that the R485H mutant was nearly devoid of any catalytic activity, that the S111P mutation did not affect the enzyme activity, and that the known K651R polymorphism was associated with activity slightly higher than that of the wild type. Using MDCK cells, we showed that translocation to the Golgi in response to serum activation was impaired for the S111P mutant but not for the other mutants. Using immortalized mouse lung fibroblasts lacking endogenous cPLA(2)α activity, we showed that both mutations S111P and R485H/K651R caused a profound defect in the enzyme catalytic activity in response to cell stimulation with serum. Taken together, our results show that the S111P mutation hampers calcium binding and membrane translocation without affecting the catalytic activity, and that the mutation R485H does not affect membrane translocation but blocks catalytic activity that leads to inactivation of the enzyme. Interestingly, our results show that the common K651R polymorphism confers slightly higher activity to the enzyme, suggesting a role of this residue in favoring a catalytically active conformation of cPLA(2)α. Our results define how the mutations negatively influence cPLA(2)α function and explain the inability of the proband to release arachidonic acid for eicosanoid production.

Indexed as

MutationAnimalsBiocatalysisCell LineDogsGroup IV Phospholipases A2HumansMiceMice, KnockoutProtein TransportGroup IV Phospholipases A2

Identifiers

PMID21247147
PMCPMC3051024
OpenAlexW2011165702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.